Ipamorelin: two trials, and the one that mattered missed
Ipamorelin is the peptide on this menu with a real drug-development history, and that history is the argument against it. A pharmaceutical company took it into a phase 2 trial for postoperative ileus, gave it intravenously to 114 patients, and found no significant difference from placebo on the endpoint it was there to move. It is also the only peptide in this group the FDA placed in category 2 under the 503B policy rather than simply logging a withdrawn nomination.
What this comes down to
- Two randomized trials exist: a 1999 pharmacokinetic study in volunteers and a 2014 phase 2 trial in bowel-resection patients.
- The phase 2 missed. Median time to a first tolerated meal was 25.3 hours on ipamorelin against 32.6 on placebo, which the trial reports as not statistically significant.
- The FDA places ipamorelin acetate in category 2 under its 503B interim policy, nominated September 29, 2023, and separately lists it among the withdrawn nominations.
- The agency's entry says a published study identified serious adverse events including death with intravenous ipamorelin for gastric motility. We could not identify which publication it means.
The trial a drug company actually ran
Ipamorelin is a ghrelin-receptor agonist, and ghrelin stimulation speeds up the gut. That is a testable idea, and somebody tested it. A multicenter, double-blind, placebo-controlled phase 2 study enrolled 117 adults having open or laparoscopic bowel resection, of whom 114 made up the safety and modified intent-to-treat populations, and gave intravenous ipamorelin at 0.03 mg/kg twice daily from postoperative day one until discharge or day seven[1].
The key endpoint was time from the first dose to tolerating a standard solid meal. Median 25.3 hours on ipamorelin, 32.6 on placebo, and the paper reports that as not significant. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. The authors' conclusion is that the dose was well tolerated and that there were no significant differences between ipamorelin and placebo on the key or secondary efficacy endpoints. It is one of two randomized trials of this peptide indexed in PubMed[3]; the other is a 1999 pharmacokinetic study in volunteers. A 2026 structured review of injectable peptides in sports medicine puts ipamorelin with the rest of the growth-hormone-axis secretagogues: investigational, uncertain safety, product quality concerns[4].
Most of the peptides sold beside this one have never been measured against a placebo at all — TB-500 has zero trials and BPC-157 has zero. Ipamorelin has one that was designed properly and came back flat. That is information about the peptide, not a gap in the record, and it is being sold as though it were the second thing.
PubMed, via the E-utilities API
ipamorelin AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 2. Positive control — semaglutide, identical filter — returned 316 through the identical filter in the same session.
Unfiltered, ipamorelin returns 54 records, most of them animal work and review articles. The two trials are the 2014 phase 2 above and a 1999 pharmacokinetic-pharmacodynamic study in human volunteers. The second control, a fabricated peptide name, returned 0 through the same filter in the same session.
The one placement that is not a withdrawn nomination
Most peptides on these menus reach the FDA's compounding page as nominations somebody later pulled. Ipamorelin acetate is on that page twice: once in the live category 2 table, under the 503B interim policy, with a nomination date of September 29, 2023, and again in the withdrawn table with a note saying it also appears above[2]. Category 2 is the bucket for substances where the agency has identified significant safety risks and declines to extend the enforcement grace period it gives category 1.
“Compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization. A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.”
[2]
The only published trial of intravenous ipamorelin for gastric motility that we could find is the 2014 phase 2, and its abstract reports no deaths and describes the dose as well tolerated. We could not identify which publication the agency is referring to, and we are not going to guess. Both statements are reproduced here as their authors made them. If you are weighing this peptide, that unresolved gap is itself part of the answer.
How it is actually sold
Across the 190 sellers we have read, one priced line names ipamorelin, and it is a blend — ipamorelin with CJC-1295, sold as one protocol at one price by Live Vital. Blending is the norm for this pair, and it has a consequence worth stating plainly: neither peptide was studied that way. The 2014 trial gave ipamorelin alone, intravenously, in a hospital. The CJC-1295 trial gave CJC-1295 alone, subcutaneously, to healthy adults. There is no trial of the combination.
Both are also compounded preparations, which means the questions about the vial apply on top of the questions about the molecule — what a certificate of analysis does and does not cover is the place to start. And the FDA's own text flags the specific reason ipamorelin is hard to characterize: it contains unnatural amino acids.
Questions people actually ask
Did the ipamorelin trial work?
No. The phase 2 trial in bowel-resection patients found a median time to first tolerated meal of 25.3 hours on ipamorelin against 32.6 on placebo, reported as not statistically significant, with no significant differences on the secondary endpoints either.
Is ipamorelin FDA-approved?
No. There is no approved drug product with ipamorelin as an active ingredient, and the FDA has placed ipamorelin acetate in category 2 of its compounding interim policy under section 503B, which is the category for substances where it has identified significant safety risks.
Why is ipamorelin usually sold together with CJC-1295?
Because the two act at different points on the same axis — one at the ghrelin receptor, one as a long-acting growth-hormone-releasing hormone analog — so combining them is a plausible idea. It is also an untested one: no randomized trial of the combination exists in PubMed.
What does the FDA say about ipamorelin's safety?
It writes that compounded ipamorelin may pose an immunogenicity risk from aggregation or peptide-related impurities, that its unnatural amino acids complicate characterization, and that a published study identified serious adverse events including death with intravenous administration for gastric motility.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014. PMID 25331030 · doi:10.1007/s00384-014-2030-8117 adults undergoing bowel resection were enrolled and 114 formed the safety and modified intent-to-treat populations; intravenous ipamorelin 0.03 mg/kg twice daily was given from postoperative day 1 to day 7 or discharge; median time to first tolerated meal was 25.3 hours against 32.6 for placebo (p = 0.15); treatment-emergent adverse events occurred in 87.5% against 94.8%; the authors conclude that there were no significant differences between ipamorelin and placebo on the key and secondary efficacy endpoints.
- 2.Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026Ipamorelin acetate appears in the category 2 table under the 503B interim policy with a nomination date of September 29, 2023, and again in the withdrawn-nominations table; the agency's text cites immunogenicity risk from aggregation or peptide-related impurities, unnatural amino acids complicating characterization, and a published study identifying serious adverse events including death with intravenous administration for gastric motility.
- 3.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-11, ipamorelin returned 54 records in total and 2 randomized controlled trials with the human indexing tag, against 316 for semaglutide and 0 for a fabricated peptide name through the identical filter in the same session.
- 4.Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Reviews, 2026. PMID 42160466 · doi:10.2106/JBJS.RVW.26.00027Growth hormone axis secretagogues including ipamorelin are characterized as investigational, with uncertain safety profiles and product quality concerns.
Key figures